Chengdu Olymvax Biopharmaceuticals Inc (688319.SH) submitted an application for the issuance of H shares, and the materials have been accepted by the China Securities Regulatory Commission.

Chengdu Olymvax Biopharmaceuticals Inc (688319.SH) has announced that on November 25, 2025, the company submitted an application to the Hong Kong Stock Exchange for the overseas public offering of shares (H shares) and listing on the main board of the Hong Kong Stock Exchange. The application materials for this issuance and listing were published on the Hong Kong Stock Exchange website on the same day. The company has also submitted the application materials for the issuance and listing to the China Securities Regulatory Commission in accordance with relevant regulations, and recently received acknowledgment from the China Securities Regulatory Commission.